pharma
© Peter Scott

Looming tariffs on imported pharmaceuticals could push up the cost of US drugs by $51bn a year, a report commissioned by the pharma lobby warns.

This would undermine competitiveness for US-produced drugs in international markets, and result in price rises for domestic consumers of up to 12.9%, if fully passed on.

And Johnson & Johnson CEO Joaquin Duato said in an earnings call discussing the firm’s Q1 results that tariffs could create supply chain disruptions.

Please Register

To continue reading, please login or register for full access to our free content
Loadstar subscriber
New Loadstar subscriber REGISTER

Comment on this article


You must be logged in to post a comment.